SOLTI 1303 PATRICIA II - cohort PATRICIA trial
Clinical Trial Program
PATRICIA is a prospective,open-label, multicenter phase II trial that aims to assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced BC.
PATRICIA II was designed to include only patients with HR+/HER2+, PAM50 LuminalA/B tumors to receive palbociclib, trastuzumab and ET versus treatment of physician’s choice (TPC).
Phase II
Status
Recruiting
Tumour subtype:
HER2+, HR+, Biomarker driven
Scenario
Locally Advanced or Metastatic
Sites
